Cargando…
Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer
Colorectal cancer (CRC) is the third leading cause of cancer deaths, and while mortality has largely improved in the developed world, five-year survival for metastatic disease remains dismally low at only 15%. Fortunately, nearly a dozen targeted therapies and immunotherapies have been FDA approved...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723550/ https://www.ncbi.nlm.nih.gov/pubmed/31366129 http://dx.doi.org/10.3390/medsci7080083 |